BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Dimas Covas, director, Butantan Institute
Approval likely even with new data

Brazil says Sinovac COVID-19 vaccine is about 50% effective, much lower than earlier results

Jan. 13, 2021
By Sergio Held
CAJICA, Colombia – Authorities in Brazil released new efficacy data for Sinovac Biotech Ltd.'s COVID-19 vaccine Coronavac that surprised on the downside, suggesting the vaccine could be much less effective than initially indicated for preventing symptomatic infections.
Read More

Other news to note for Jan. 12, 2021

Jan. 13, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbott, Absci, Artms, Avista Capital Partners, Biolase, Blue Earth Diagnostics, Capital Constellation, CardiAI, Cerenovus, Denovium, Dental Care Alliance, Endospan, Fidelis Sustainability Distribution, Fineheart, Gbt Technologies, Irras, Itamar Medical, Movemedical, Onward, Pulse Biosciences, Shimmer Research, Smith+Nephew, Spry Health, Statlab Medical Products, Strata Skin Sciences, Synaptive Medical, Teva, Treo Ventures, Turner Imaging Systems.
Read More

Other news to note for Jan. 13, 2021

Jan. 13, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Acorda, Actinium, Astellas, Auravax, Biodesix, Cytokinetics, Cytovia, Diurnal, Eloxx, Esperion, Essa, Genevant, Genmab, Genprex, Graphite, Hemogenyx, Hibercell, J&J, Jaguar, Jasper, Ji Xing, Kaken, Kamada, Khondrion, Ligand, Marker, Merck, Napo, Numab, Omega RDIF, Regeneron, Roche, Salarius, Sarepta, Serometrix, Taysha, União Química, Urogen .
Read More

In the clinic for Jan. 13, 2021

Jan. 13, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adastra, Arcutis, Celltrion, Cytokinetics, Fosun, Gensight, Jounce, Kintara, Leo, Philogen, Regeneron, Rockwell, Sanofi, Sorrento, Synairgen.
Read More
Regulatory front

Regulatory front for Jan. 13, 2021

Jan. 13, 2021
The latest global regulatory news, changes and updates affecting biopharma.
Read More
Rapid testing result for COVID-19

In attempt to quell a pandemic, the U.K. launches free COVID-19 testing program

Jan. 12, 2021
By Nuala Moran
LONDON – The U.K. has launched a nationwide free testing program to diagnose COVID-19 in people who are asymptomatic, in the latest attempt to stem the tide of infection. Through the program, all local authorities will provide rapid testing using lateral flow devices. In addition, companies will be provided with free tests to set up workplace screening. Initially, the focus of both strands will be on getting people who cannot work from home to come forward for regular checks.
Read More

Regulatory actions for Jan. 12, 2021

Jan. 12, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biomerica, Cognito Therapeutics, Cytosorbents, Jud Care, Medskin Solutions Dr. Suwelack, Microvention, Ortho, Quanterix, Therapixel.
Read More

Regulatory actions for Jan. 12, 2021

Jan. 12, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bayer, Creative Medical, Diurnal, Innovent, Lantheus, Merck, Moderna, Neurosense, Veralox.
Read More

Other news to note for Jan. 12, 2021

Jan. 12, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Absci, Adagene, Adaptive, Adelia, Allyx, Amneal, Astrazeneca, Artms, Atai, Avantgen, Beactica, Berkeley Lights, Bristol Myers Squibb, Capricor, Cybin, Denovium, Dioscure, Dragonfly, Essa, Gilead, Homology, IGM, Immunitybio, Iosbio, Kashiv, La Jolla, Lonza, Medivir, Paion, Pfizer, Pharmadrug, Pharmenable, Point, Recognify, Recombinetics, Sairiyo, Sanofi, Sosei, Telix, Trillium, Valneva, Vedanta, Verve, Vir.
Read More

In the clinic for Jan. 12, 2021

Jan. 12, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ascletis, Blue Earth, Bone Therapeutics, Caladrius, Cellectar, Clearside, Clovis, Gannex, GSK, GT, Helsinn, Lipocine, Merus, Mesoblast, Ox2, Resverlogix, Rezolute, Roche, Taiho, Terns, Vir, Vitalis.
Read More
Previous 1 2 … 301 302 303 304 305 306 307 308 309 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing